Selected novel agents that have been studied for treatment of PTCLs in the frontline or relapsed/refractory settings
| Drug(s) . | Mechanism . |
|---|---|
| Brentuximab vedotin (SGN-35) | Antibody-drug conjugate consisting of a chimeric anti-CD30 monoclonal antibody linked to cytotoxic agent monomethyl auristatin E |
| Pralatrexate | Selective antifolate analogue inhibiting dihydrofolate reductase, resulting in dysregulated purine and pyrimidine synthesis |
| Romidepsin, belinostat, vorinostat | Histone deacetylase inhibitors (interfere with histone and chromatin modification) |
| Lenalidomide | Immunomodulatory agent enhancing ubiquitin ligase activity and proteasomal degradation of disease-specific proteins |
| Azacitidine | DNA hypomethylating agent (decrease the amount of cellular DNA methylation, allowing for tumor suppressor gene expression) |
| Duvelisib, linperlisib, tenalisib | Oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and/or PI3K-γ isoforms |
| Tazemetostat, valemetostat, tulmimetostat, HH2853 | Small molecules inhibiting histone methyltransferase activity of EZH1/2 (dual inhibitors) or EZH2 alone |
| Ruxolitinib, golidocitinib | Janus kinase (JAK) inhibitors interfering with dysregulated cytokine signaling |
| Crizotinib, alectinib | Oral small-molecule tyrosine kinase inhibitor with binding specificity for ALK and ROS1 |
| Soquelitinib (CPI-818) | Oral small-molecule irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) disrupting T-cell receptor signaling through ITK-mediated signal transduction |
| Drug(s) . | Mechanism . |
|---|---|
| Brentuximab vedotin (SGN-35) | Antibody-drug conjugate consisting of a chimeric anti-CD30 monoclonal antibody linked to cytotoxic agent monomethyl auristatin E |
| Pralatrexate | Selective antifolate analogue inhibiting dihydrofolate reductase, resulting in dysregulated purine and pyrimidine synthesis |
| Romidepsin, belinostat, vorinostat | Histone deacetylase inhibitors (interfere with histone and chromatin modification) |
| Lenalidomide | Immunomodulatory agent enhancing ubiquitin ligase activity and proteasomal degradation of disease-specific proteins |
| Azacitidine | DNA hypomethylating agent (decrease the amount of cellular DNA methylation, allowing for tumor suppressor gene expression) |
| Duvelisib, linperlisib, tenalisib | Oral dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-δ and/or PI3K-γ isoforms |
| Tazemetostat, valemetostat, tulmimetostat, HH2853 | Small molecules inhibiting histone methyltransferase activity of EZH1/2 (dual inhibitors) or EZH2 alone |
| Ruxolitinib, golidocitinib | Janus kinase (JAK) inhibitors interfering with dysregulated cytokine signaling |
| Crizotinib, alectinib | Oral small-molecule tyrosine kinase inhibitor with binding specificity for ALK and ROS1 |
| Soquelitinib (CPI-818) | Oral small-molecule irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) disrupting T-cell receptor signaling through ITK-mediated signal transduction |